Merck & Co., Inc. (MRK) Joins Forces With M2Gen To Explore The ORIEN Avatar Research Program
Merck & Co., Inc.
Author Archive - Market Exclusive
NeRRe, A GlaxoSmithKline PLC (ADR) (GSK) Spinout Raises £23 Million For NK Antagonists
NeRRe Therapeutics, which is a GlaxoSmithKline PLC (ADR) (NYSE:GSK) spinout, has raised £23 million ($28 million) in a Series B financing round.
For Shire PLC (ADR) (SHPG) Securing Hemophilia Market With Long Acting Version Is Crucial
Stocks may be at new highs and sentiment bullish, but the exuberance hasn’t infected every sector.
What Does The Panel Cancellation Mean For Neurocrine Biosciences, Inc. (NBIX)?
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) just announced that that the FDA has cancelled the Psychopharmacologic Drugs Advisory Committee meeting for INGREZZA.
GrandOmics Endorses Pacific Biosciences of California (PACB) Sequel System With New Purchase
Pacific Biosciences of California (NASDAQ:PACB) has received a purchase order for its sequel systems from GrandOmics.
Federal Judge Orders State Provide Mumia Abu-Jamal With HCV Treatment by Gilead Sciences, Inc. (GILD)
A federal judge in Pennsylvania has admonished the state for restricting inmates’ access to drugs and particularly those for hepatitis C.
Bristol-Myers Squibb Co (BMY) Agrees To Extend Research With Five Prime Therapeutics Inc (FPRX)
Bristol-Myers Squibb Co (NYSE:BMY) has opted to extend the research term of its discovery collaboration agreement with Five Prime Therapeutics Inc (NASDAQ:FPRX).
AEterna Zentaris Inc. (USA) (AEZS) Is Down, But Probably Not Out
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) is taking a major hit premarket, having put out data from its lead trial after hours on Wednesday.
Allergan Plc (AGN) Explodes After FDA Approval Of Natrelle Inspira
Allergan Plc (NYSE:AGN) is trading higher in the market early into the New Year, after clinching FDA approval for its breast implant treatment, Natrelle Inspira.
Sanofi SA (ADR) (SNY) Hit With Cease And Desist Order On Dengue Vaccine Ads In The Philippines
The Philippines Food and Drug Administration has ordered Sanofi SA (ADR) (NYSE:SNY) to desist from advertising its dengue vaccine or face major consequences.
Taking A Look At CymaBay Therapeutics Inc (CBAY)’s Big Deal
CymaBay Therapeutics Inc (NASDAQ:CBAY) is running up on the news that it has scored an exclusive licensing agreement with Kowa Pharmaceuticals America, Inc.
What We’re Watching In Biotech For January: Otonomy Inc (OTIC) And TESARO Inc (TSRO)
It’s going to be a busy month in the biotechnology sector.
AstraZeneca PLC (ADR) (AZN) Planning Tagrisso Label Expansion To Shore Up Earnings
AstraZeneca plc (ADR) (NYSE:AZN) share price could receive a major boost on the company pursuing a label expansion for its blockbuster Tagrisso.
Mylan NV (MYL), AbbVie Inc (ABBV) Sanofi SA (ADR) (SNY) In Spotlight Over Price Hikes
A Vermont drug price transparency bill threatens to make it hard for drug makers to increase drug prices without explanations.
Endologix, Inc. (ELGX) Updates Physicians Concerning Stent Graft Treatment Devices
Following discussions with the Food and Drug Administration, Endologix, Inc.
Is It Worth Following Celgene Corporation (CELG) Into Jounce At IPO?
Earlier this year, we looked at a privately held biotech called Jounce Therapeutics.
Inotek Pharmaceuticals Corp (ITEK) Is About To Release Some Game Changing Data
Inotek Pharmaceuticals Corp (NASDAQ:ITEK) kicked off a phase III trial back in 2015, investigating its lead candidate, Trabodenoson, in glaucoma patients.
AstraZeneca plc (ADR) (AZN) CEO Claims The Drug Approval Process Of NHS Is Counterproductive
AstraZeneca plc (ADR) (NYSE:AZN)’s chief executive officer has said that the long negotiation process that the NHS undertakes with drugmakers before approving medications is...
Lead Plaintiff Sought For Class Action Lawsuit Filed Against Illumina, Inc. (ILMN)
A lead plaintiff is being sought by Lundin Law PC in the lawsuit that the law firm has filed against Illumina, Inc. (NASDAQ:ILMN).
Protalix Biotherapeutics Inc (PLX) Could Run Up On Interim CF Data
Double-digit gains across a session or two in small cap biotech aren’t all that rare.
Securities Law Firms Seeking Lead Plaintiffs In Class Action Suit Against Teva Pharmaceutical Industries Ltd (ADR) (TEVA)
Brower Piven, a law firm specializing in securities litigation, is sending out an appeal reminding investors of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) that the...
Regulator Demands Divestiture In Asset Swap Deal Between Boehringer, Sanofi SA (ADR) (SNY)
Boehringer Ingelheim, a German pharmaceutical firm, are involved in plans to divest of five kinds of products for animal health.
Synergy Pharmaceuticals Inc (SGYP) Moves Closer To Expanding Plecanatide Label
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has provided an update on topline results from a Phase 3 study of its candidate plecanatide.
Fortress Biotech Inc (FBIO) Spike: Is It Deserved, And What’s Next?
So here’s an example of just how inefficient the smaller end of the biotech sector can be.
Sanofi SA (ADR) (SNY) Files Suit Against Novo Nordisk A/S (ADR) (NVO) Over False Insulin Claims
Novo Nordisk A/S (ADR) (NYSE:NVO) has been sued by Sanofi SA (ADR) (NYSE:SNY) for making false claims.
Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Agrees To Settle With The SEC Over Corruption Charges
The Securities and Exchange Commission has revealed that Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) will have to pay more than $500 million after being found to have...
Spring Bank Pharmaceuticals Inc (SBPH) An Ace Up Gilead Sciences, Inc. (GILD)’s Sleeve
While most westerners don’t have to worry about hepatitis B virus (HBV) due to currently available and effective vaccines, HBV is still an incurable disease, with a staggering...
Anthera Pharmaceuticals Inc (ANTH) Looks Good For A Recovery
Anthera Pharmaceuticals Inc (NASDAQ:ANTH) is heading into the close of the year more than 60% down on its early week market cap, on the release of some seemingly disappointing...
Medtronic PLC (MDT) Soars With The Approval Of CoreValve Evolut R System
Medtronic PLC (NYSE:MDT) is expanding, thanks to the reimbursement approval and launch of its CoreValve Evolut R System.
Amicus Therapeutics, Inc. (FOLD) Announces The Closure Of Its Senior Convertible Notes
Amicus Therapeutics, Inc.
FDA Agrees To Review IBRANCE (palbociclib) From Pfizer Inc. (PFE)
The U.S. Food and Drug Administration (FDA) has agreed to review a supplemental New Drug Application (sNDA) of CDK 4/6 inhibitor, IBRANCE (palbociclib) from Pfizer Inc.
Sucampo Pharmaceuticals, Inc. (SCMP) Announces Its New Debt Offering Of Convertible Notes
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has announced the pricing of a $260.0 million aggregate principal amount of 3.25% convertible senior notes, due 2021.
Akebia Therapeutics Inc (AKBA) Sells Partial US Rights For Vadadustat To Otsuka
Akebia Therapeutics Inc (NASDAQ:AKBA) has surrendered 50% of U.S.
GlaxoSmithKline PLC (ADR) (GSK) Phase 3 Trials Looks Positive: Will Gilead Sciences, Inc. (GILD) Endure?
Efforts by GlaxoSmithKline plc (ADR) (NYSE:GSK) in carrying out a large study on its new HIV drug are yielding positive results.
AbbVie Inc (ABBV) Awaits NDA Approval For Hepatitis C Treatment
A New Drug Application (NDA) by AbbVie Inc (NYSE:ABBV) that will be used for the treatment of Hepatitis C is at the mercy the U.S. Food and Drug Administration.
Three Companies Set To Benefit From The 21st Century Cures Act: Who And Why
With all the political turmoil in the United States and across the Western world of late, it can be easy to lose track of less sensationalist politics, like the passing of bills...
Can Loxo Oncology Inc (LOXO) Candidate Larotrectinib Pass Regulatory Test?
Loxo Oncology Inc (NASDAQ:LOXO) is targeting to file for regulatory approval of its gene mutation cancer drug candidate larotrectinib at the end of next year or early in 2018.
Novartis AG (ADR) (NVS) Agrees To $50 Million Deal With Conatus Pharmaceuticals Inc (CNAT)
Novartis AG (ADR) (NYSE:NVS) and Conatus Pharmaceuticals Inc (NASDAQ:CNAT) will jointly develop Conatus drug emricasan.
Bristol-Myers Squibb Co (BMY) And Pfizer Inc. (PFE) Agree To $50 Million Loan To Portola Pharmaceuticals Inc (PTLA)
There is a need for additional funding towards the development and clinical studies of AndexXa, a new compound that is a prospective antidote for Factor Xa inhibitors.
Here’s What’s Next For Evoke Pharma Inc (EVOK)
Evoke Pharma Inc (NASDAQ:EVOK) is running up on news of a successful meeting with the FDA, during which the company got confirmation of what amounts to a streamlined path to commercialization...
Amicus Therapeutics, Inc. (FOLD): Breaking Down The Raise
Amicus Therapeutics, Inc. (NASDAQ:FOLD) just announced a convertible senior notes offering, and the company is trending down on he back of the news.
Shire PLC (ADR) (SHPG) Looks To Xenetic Biosciences Inc (XBIO) To Cement Hemophilia Market Share
Hemophilia, a genetic blood disease where patients lack a blood-clotting protein, is a $7 billion annual market.
Here’s Our Take On Horizon Pharma PLC (HZNP)’s Fall Out And Regeneron Pharmaceuticals Inc (REGN)’s EMA Hit
Thursday was a big day for two companies, in two very different ways, in the biotech space.
EMA Reviews Regeneron Pharmaceuticals Inc (REGN), Sanofi SA (ADR) (SNY) Dupixent MAA
The European Medicines Agency (EMA) has recently accepted to review the Marketing Authorization Application (MAA) of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (...
AstraZeneca PLC (ADR) (AZN) Cuts Jobs, Signs New Collaboration With Eli Lilly And Co (LLY)
“By diligently prioritizing, we will continue to successfully launch and commercialize new medicines, meet the needs of our customers and patients, and ultimately help AstraZeneca...
Biotech Movers And Shakers: Cascadian Therapeutics Inc (USA) (CASC) And Anthera Pharmaceuticals Inc (ANTH)
Another day done in biotech, and we’re fast closing in on the end of the week.
Voyager Therapeutics Inc (VYGR) Has Plenty Of Near Term Catalysts To Watch
The wider biotech space took a hit mid week, on the back of comments made by Donald Trump, suggesting a price crackdown in the sector.
Eli Lilly And Co (LLY) Discusses Job Cuts
Eli Lilly and Co (NYSE:LLY) has recently confirmed that it will cut jobs following the release of disappointing results from a clinical trial evaluating solanezumab, affecting...
Celgene Corporation (CELG) Presents Encouraging Phase 2 tnAcity Clinical Trial Results, Decides Not To Pursue Phase 3
Celgene Corporation (NASDAQ:CELG) has recently unveiled the results from the randomized, Phase 2 tnAcity clinical trial evaluating Abraxane for injectable suspension as part of...
SAGE Therapeutics Inc (SAGE): What Just Happened, And What’s Next?
SAGE Therapeutics Inc (NASDAQ:SAGE) is running up on a trial update this week, with the company currently trading a little over 12% higher than its close on Friday.
